Lanham O'Dell & Company, Inc. Catalyst Pharmaceuticals, Inc. Transaction History
Lanham O'Dell & Company, Inc.
- $165 Million
- Q1 2025
A detailed history of Lanham O'Dell & Company, Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Lanham O'Dell & Company, Inc. holds 15,000 shares of CPRX stock, worth $325,500. This represents 0.22% of its overall portfolio holdings.
Number of Shares
15,000
Previous 15,000
-0.0%
Holding current value
$325,500
Previous $313,000
15.97%
% of portfolio
0.22%
Previous 0.17%
Shares
10 transactions
Others Institutions Holding CPRX
# of Institutions
390Shares Held
99.9MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$406 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$184 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$120 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$74.3 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$68 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.23B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...